We advised financial advisers to Abcam on the transaction

Davis Polk advised Lazard Ltd. and Morgan Stanley as financial advisers to Abcam plc on its approximately $5.7 billion acquisition by Danaher Corporation. Under the terms of the agreement, Danaher will acquire outstanding shares of Abcam for $24.00 per share in cash. The transaction is anticipated to close mid-2024 and is subject to customary conditions, including receipt of applicable regulatory approvals and Abcam shareholder approval.

Founded in 1998 and headquartered in Cambridge, United Kingdom, Abcam is a life sciences and biotechnology company offering the scientific community highly validated antibodies, reagents, biomarkers and assays to address targets in biological pathways that are critical for advancing drug discovery, life sciences research and diagnostics.

Danaher Corporation, based in Washington DC, designs, manufactures and markets professional, medical, industrial and commercial products and services. Its offerings include water quality analysis and treatment systems, life sciences and diagnostics equipment, industrial automation and motion control systems, and cardiovascular, diabetes and irradiation devices.

The Davis Polk corporate team included partner Phillip R. Mills and associate Jessica L. Teng. All members of the Davis Polk team are based in the New York office.

Copy link to share post